HUTCHMED (China) Ltd ADR HCM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HCM is a good fit for your portfolio.
News
-
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
-
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
-
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
-
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
-
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
-
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
-
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
-
HUTCHMED to Announce 2023 Final Results
Trading Information
- Previous Close Price
- $18.25
- Day Range
- $18.10–18.73
- 52-Week Range
- $10.68–20.73
- Bid/Ask
- $18.55 / $19.00
- Market Cap
- $3.14 Bil
- Volume/Avg
- 57,768 / 133,111
Key Statistics
- Price/Earnings (Normalized)
- 29.53
- Price/Sales
- 3.51
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.13%
Company Profile
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,990
- Website
- https://www.hutch-med.com
Comparables
Valuation
|
Metric
|
HCM
|
09926
|
06628
|
|---|---|---|---|
Price/Earnings (Normalized) | 29.53 | 19.16 | — |
Price/Book Value | 3.96 | 7.53 | 0.73 |
Price/Sales | 3.51 | 7.85 | 11.54 |
Price/Cash Flow | 19.88 | 14.40 | — |
Price/Earnings
HCM
09926
06628
Financial Strength
|
Metric
|
HCM
|
09926
|
06628
|
|---|---|---|---|
Quick Ratio | 2.58 | 5.46 | 1.50 |
Current Ratio | 2.72 | 6.43 | 1.61 |
Interest Coverage | 30.20 | 26.84 | −33.53 |
Quick Ratio
HCM
09926
06628
Profitability
|
Metric
|
HCM
|
09926
|
06628
|
|---|---|---|---|
Return on Assets (Normalized) | 11.29% | 24.23% | −22.79% |
Return on Equity (Normalized) | 19.17% | 44.26% | −38.31% |
Return on Invested Capital (Normalized) | 13.58% | 29.66% | −26.22% |
Return on Assets
HCM
09926
06628
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Mbqxjzstbz | Yxvddv | $70.9 Bil | |
ZTS
| Zoetis Inc Class A | Hdtpvvbgfh | Sxz | $68.9 Bil | |
HLN
| Haleon PLC ADR | Qmrsdmys | Tnnc | $37.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Cnqfpsp | Hkgf | $14.7 Bil | |
VTRS
| Viatris Inc | Zfczjnq | Jyqw | $13.7 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Dptwsbskp | Bybq | $11.9 Bil | |
CTLT
| Catalent Inc | Qvqzdryr | Fbwpmg | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Vbfvgmpk | Dvq | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Hyvvyfnbd | Hdkk | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Mtvmjgjss | Pvcvm | $3.5 Bil |